IONS
Ionis Pharmaceuticals Inc
45.80$
+1.9%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 87.5% | 87.5% | 87.4% | 88.3% | 82.8% | 84.2% | 89.1% | 89.8% | 86.9% | 88.4% | 87.2% | 84.9% | |
| 76.3% | 81.5% | 72.9% | 77.4% | 78.1% | 77.3% | 79.2% | 81.0% | 10.9% | 13.4% | 8.1% | 10.6% | |
| 84.8% | 84.1% | 73.2% | 77.4% | 78.1% | 77.3% | 79.2% | 81.0% | 78.8% | 78.0% | 76.5% | 76.0% | |
| 0.4% | 1.2% | 11.8% | 4.8% | 0.5% | 1.9% | 3.2% | 2.4% | 1.0% | 3.3% | 3.1% | 1.9% | |
| 0.7% | 0.7% | 0.8% | 0.8% | 0.3% | 0.6% | 0.9% | 0.9% | 0.9% | 0.2% | 0.4% | 0.3% | |
| 9.3% | 9.4% | 10.2% | 9.2% | 5.0% | 4.8% | 7.6% | 6.8% | 2.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 2.1% | 2.0% | 2.2% | 1.7% | 0.9% | 0.8% | 1.2% | 1.1% | – | – | – | – | |
| 73.0% | 79.0% | 89.1% | 68.3% | 55.5% | 47.9% | 64.7% | 70.4% | 77.4% | 87.1% | 80.4% | 86.1% | |
| 12.1% | 15.6% | 14.7% | 17.0% | 10.5% | 8.4% | 12.1% | 9.2% | 12.3% | 15.0% | 10.3% | 22.2% | |
| 0.3% | 0.9% | 0.1% | 0.1% | 0.5% | 0.1% | 12.3% | 0.1% | 0.3% | 1.8% | 0.3% | 12.9% | |
| 1.9% | 3.0% | 2.3% | 1.9% | 1.1% | 0.5% | 0.7% | 0.5% | 0.7% | 0.9% | 1.4% | 0.8% | |
| 47.6% | 41.6% | 54.9% | 44.8% | 23.5% | 23.8% | 21.6% | 46.8% | 46.7% | 41.1% | 41.5% | 38.2% | |
| 27.0% | 21.0% | 10.9% | 31.7% | 44.5% | 52.1% | 35.3% | 29.6% | 22.6% | 12.9% | 19.6% | 13.9% | |
| -105.3% | -114.5% | -129.5% | -89.8% | -36.3% | -21.9% | -52.3% | -44.4% | -56.4% | -60.1% | -74.9% | -74.7% | |
| 12.3% | 12.5% | 13.3% | 9.5% | 5.0% | 4.4% | 5.8% | 5.4% | 5.6% | 4.8% | 5.0% | 4.5% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.